Des améliorations rapides, significatives et durables de la vision à douze mois ont été rapportéesAmélioration concordante des mesures des résultats secondaires clésLa dose d'enregistrement cible du sepofarsen a été bien tolérée avec un profil risque/bénéfice fa
… ProQR Announces that QR-010 Meets the Primary Endpoint in a … LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … results of PQ-010-002 will be presented today by Noreen R. Henig M.D. and John P. Clancy M.D. at the North American …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … to present new data from the InSight study in H2 2021. ProQR’s Presentation Presentation title: Safety and efficacy … Congenital Amaurosis type 10 (LCA10) Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
… ProQR Reaches Agreement with the FDA on Design of Phase 2/3 … & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development of ProQR. “Our regulatory discussions have been very …
… ProQR Announces Positive Findings From an Interim Analysis in … pandemic expected to impact timelines for the pipeline ProQR anticipates its cash runway will fund operations into … Executive Vice President of Research and Development of ProQR. “We are pleased with the current safety profile and …
… ProQR to Present at the Retinal Cell and Gene Therapy … & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Leber congenital amaurosis (LCA10) Presenter: Dr. Stephen R. Russell, Iowa University Presentation type: Oral …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … information or to RSVP, please contact Sariette Witte at ir@proqr.com . OTS The abstract titled: 'QR-010 penetrates …
… ProQR to present QR-010 data at the European Cystic Fibrosis … QR-010 can treat all manifestations of CF,” said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “I am very pleased that enrollment of the Phase 1b …